References - Shodhganga : a reservoir of Indian theses …shodhganga.inflibnet.ac.in/bitstream/10603/28261/15/15_references.pdf · Skeel RT, Khleif SN. Handbook of cancer chemotherapy

References

Dept of Pharmaceutics, JSSCP, Mysore 376

1. Dixit AS, Kulkarni PK. Novel eatable silk fibroin gels containing salbutamol sulphate

for dysphagic and geriatric patients. Asian J Pharm. 2012;6:60-6.

2. Dixit AS, Parthasarathi KK, Hosakote GS. Gels and jellies as a dosage form for

dysphagia patients: a review. Curr Drug Ther. 2011;6:79-6.

3. Andersen O, Zweidorff OK, Hjelde T, Rodland EA. Problems when swallowing

tablets: A questionnaire study from general practice. Tidsskr Nor Laegeforen. 1995;

115:947-9.

4. Guidance for Medication Assessment in Patients with Swallowing (Dysphagia) or

Feeding Disorders Pharmacy Benefits Management- Strategic Healthcare Group

(PBM). Available from:

http://www.pbm.va.gov/Clinical%20Guidance/Clinical%20Recommendations/Dysph

agia,%20Recommendations%20for%20Medication%20Assessment.pdf (assessed on

15th July, 2010).

5. CPLOL– Prevention Commission Dysphagia Review 2004-2005. Available from:

www.cplol.eu/files/CPLOL_dysphagiareport_en.pdf (assessed on 12th July, 2010).

6. Kottke MK, Stetsko G, Rosenbaum SE, Rhodes CT. Problems encountered by the

elderly in the use of conventional dosage forms. J Geriatr Drug Ther. 1990;5:77-92.

7. Paterson WG. Dysphagia in the elderly. Can Fam Physician. 1996;42:925-932.

8. Cancer. Available from: http://en.wikipedia.org/wiki/Cancer (assessed on: 10th Aug,

2012).

9. Marimuthu P. Projection of cancer incidence in five cities and cancer mortality in

India. Indian J Cancer. 2008;45:4-7.

References


10. Goel P, Singh K, Kaur A, Verma M. Oral healthcare for elderly: Identifying the needs

and feasible strategies for service provision. Ind J Dent Res. 2006;17:11-21.

11. Shavi GV, Nayak UY, Reddy MS, Karthik A, Deshpande PB, Kumar AR. et al.

Sustained release optimized formulation of anastrozole-loaded chitosan microspheres:

in vitro and in vivo evaluation. J Mater Sci: Mater Med. 2011;22:865-878.

12. Cyclophosphamide, National toxicology program, Department of Health and Human

Services, Report on Carcinogens, 12th ed. 2011. p. 124-5.

13. Ridge JA, Glisson BS, Lango MN, Feigenberg S. Head and Neck Tumors. Available

From: http://www.cancernetwork.com/cancer-management/head-and-

neck/article/10165/1802498# (assessed on: 20th June, 2012).

14. Head and neck cancer in India. Available From:

http://www.veedaoncology.com/PDF-Document/Head-

Neck%20Cancer%20In%20India.pdf (assessed on: 22nd, Mar 2012).

15. Methotrexate. Available From: http://drugsarea.com/Dets-Drugs/Methotrexatepd.html

(assessed on: 20th June, 2012).

16. Methotrexate drug information provided by Lexi-Comp. Available From:

http://www.merckmanuals.com/professional/lexicomp/methotrexate.html (assessed

on: 21th March, 2012).

17. Imatinib. Available From: http://www.rxlist.com/gleevec-drug.htm (assessed on: 10th

June, 2011).

18. Harding F. Breast cancer: Cause – Prevention - Cure. Available at:

http://books.google.co.in/books?id=0h2gDLv3MOEC&printsec=frontcover&source=

gbs_ge_summary_r&cad=0#v=onepage&q&f=false (assessed on 1st July, 2012).

References


19. Sinha VR, Aggarwal A, Srivastava S, Goel H. Influence of operational variables in

multi-particulate delayed release systems for colon-targeted drug delivery of

celecoxib using extrusion spheronization. Asian J Pharm. 2010;4:102-9.

20. Dixit AS, Kulkarni PK. Formulation and evaluation of fast disintegrating tablet

containing capecitabine for dysphagia patients. Int J Res Pharm Sci. 2012;3(4):1-8.

21. Cancer. Available from: http://www.cancer.gov/cancertopics/wyntk/cancer/page2

(assessed on: 20th Aug, 2012).

22. Cancer. Available from: http://en.wikipedia.org/wiki/Cancer. (Assessed on: 1st Aug,

2012).

23. Skeel RT, Khleif SN. Handbook of cancer chemotherapy. 8th ed. India: Lippincott

Williams & Wilkins; 2011.

24. Symptoms of cancer. Available from:

http://www.medicalnewstoday.com/info/cancer-oncology/ (assessed on: 12th June,

2012).

25. Yarbro CH, Wujcik D, Gobel BH. Cancer nursing principal and practice. 7th ed.

Massachusetts: Jones and Bartlett publishers; 2011.

26. Cancer prevention overview. Available from:

http://www.cancer.gov/cancertopics/pdq/prevention/overview/HealthProfessional


27. Cancer prevention. Available from: http://www.who.int/cancer/prevention/en/


References


28. Cancer diagnosis. Available from:

http://cancer.stanford.edu/information/cancerDiagnosis/ (assessed on: 1st Oct, 2012).

29. Gaziano JE. Evaluation and management of oropharyngeal dysphagia in head and

neck cancer. Cancer Control. 2002;9(5):400-9.

30. Matsuo K, Palmer JB. Anatomy and Physiology of Feeding and Swallowing –

Normal and Abnormal. Phys Med Rehabil Clin N Am. 2008;19(4):691-707.

31. Esophageal Dysphagia. Available from:

http://en.wikipedia.org/wiki/Esophageal_dysphagia (assessed on: 1st Oct, 2012).

32. Oropharyngeal Dysphagia. Available from:

http://en.wikipedia.org/wiki/Oropharyngeal_dysphagia (assessed on: 1st Oct, 2012).

33. Swallowing problems (dysphagia) after head and neck cancer.

http://www.asha.org/public/speech/disorders/SwallowingProbs.htm (assessed 1st Oct,

2012).

34. Balzer KM. Drug-induced dysphagia. Int J MS Care. 2000;2(1):6.

35. Cichero J, Murdoch B. Dysphagia: Foundation, Theory and Practice. UK: John

Wiley & Sons Ltd; 2006.

36. Ekberg O, Hamdy S, Woisard V, et al. Social and psychological burden of dysphagia:

Its impact on diagnosis and treatment. Dysphagia. 2002;17:139–46.

37. Spieker MR. Evaluating dysphagia. Am fam physician. 2000;61(12):3639-48.

38. Carrau RL. Evaluation and management of adult dysphagia and aspiration. Curr Opin

Otolaryngol Head Neck Surg. 2000;8:489-96.

References


39. Strowd L, Kyzima J, Pillsbury D, Valley, Bruce RR. Dysphagia dietary guidelines

and the rheology of nutritional feeds and barium test feeds. Chest. 2008;133:1397-

1401.

40. Robbins J, Hind J. Perspectives on swallowing and swallowing disorders. Dysphagia.

2008;17:259-66.

41. Germain I, Dufresne T, Gray DK. A novel dysphagia diet improves the nutrient

intake of institutionalized elders. J Am Diet Assoc. 2006;106(10):1614-23.

42. Borsadia SB, O'Halloran D, Osborne JL. Quick-Dissolving Films - A Novel

Approach to Drug Delivery. Drug Deliv Technol. 2003;3(3):63-66.

43. Siddiqui MDN, Garg G, Sharma PK. A Short Review on “A Novel Approach in Oral

Fast Dissolving Drug Delivery System and Their Patents”. Adv Biological Res, 2011;

5 (6):291-303.

44. Dahiya M, Saha S, Shahiwala AF. A Review on Mouth Dissolving Films. Curr Drug

Deliv. 2009;6:469-476.

45. Gavaskar B, Kumar SV, Sharan S, Rao YM. Overview on fast dissolving films. Int J

Pharmacy Pharm Sci. 2010;2(3):29-33.

46. Dixit RP, Puthli SP. Oral strip technology: Overview and future potential. J Control

Release. 2009;139:94-107.

47. Arun A, Amrish C, Vijay S, Kamla P. Fast dissolving oral films: an innovative drug

delivery system and dosage form. Int J ChemTech Res. 2010;2(1):576-83.

48. Apoorva M, Neha C, Geeta A. Formulation and Characterization of Fast Dissolving

Buccal Films: A Review. Der Pharmacia Lettre. 2011;3(1):152-65.

References


49. Malke S, Shidhaye S, Desai J, Kadam V. Oral films - patient compliant dosage form

for pediatrics. Internet J Pediatr Neonatol. 2010;11:2.

50. El-Setouhy DA, El-Malak NSA. Formulation of a novel tianeptine sodium

orodispersible film. AAPS PharmSciTech. 2010;11(3):1018-25.

51. Cilurzo F, Cupone I, Minghetti P, Selmin F, Montanari L. Fast dissolving films made

of maltodextrin. Eur J Pharm Biopharm. 2008;70(3):895-900.

52. Nagar P, Chauhan I, Yasir M. Insights into polymers: film formers in mouth

dissolving films. Drug Invention Today. 2011;3(12):280-89.

53. Dinge A, Nagarsenker M. Formulation and evaluation of fast dissolving films for

delivery of triclosan to the oral cavity. AAPS PharmSciTech. 2008;9(2):349-56.

54. Hiroyoshi S, Kazumi T, Misao N, Katsuhiko M, Tadao T, Hirotaka, Y et al.

Preparation of a fast dissolving oral thin film containing dexamethasone: A possible

application to antiemesis during cancer chemotherapy. Eur J Pharm Biopharm.

2009;73:361–365.

55. Nishimura M, Matsuura K, Tsukioka T, Yamashita H, Inagaki N, Sugiyama T, et al.

In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J

Pharma. 2009;368:98–102.

56. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets:

Developments, technologies, Taste-masking and clinical studies. Crit Rev Ther Drug.

2004;21(6):433–75.

57. Shukla D, Chakraborty S, Singh S, Mishra B. Mouth dissolving tablets I: An

overview of formulation technology. Sci Pharm. 2009;77:309–26.

References


58. Hirani JJ, Rathod DA, Vadalia KR. Orally Disintegrating Tablets: A Review. Trop J

of Pharma Res. 2009;8(2):161-72.

59. Shukla D, Chakraborty S, Singh S, Mishra B. Mouth dissolving tablets II: An

overview of formulation technology. Sci Pharm. 2009;77:327–341.

60. Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: Innovations in

formulation and technology. Recent Pat Drug Deliv Formul. 2008;2:258-74.

61. Harmon T. Beyond the first generation of orally disintegrating tablets. Emerging

technology. Tablets and Capsules, 2006; 3.

62. McLaughlin R, Banbury S, Crowley K. The effect of recent FDA guidance on ODT

technologies and applications. Available from:

http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=623097 (assessed

on: 1st Oct, 2012).

63. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug

delivery – a review. Pharm Sci Technol Today. 2000;3:138-45.

64. Allen LV, Wang, B. Particulate support matrix for making a rapidly dissolving tablet,

1997, US Patent 5595761.

65. Sherry R. Granules comprising paracetamol, a NSAID and a sugar alcohol made by

melt extrusion.US Patent 2008/0085308 A1.

66. Bhowmik D, Chiranjib B, Yadav J, Chandira RM, Kumar KPS. Emerging trends of

disintegrants used in formulation of solid dosage form. Der Pharmacia Lettre. 2010;

2(1):495-504.

References


67. Omidian H, Park K. Swelling agents and devices in oral drug delivery. J Drug Del Sci

Tech. 2008;18(2):83-93.

68. Jagdale SC, Fernandes NC, Kuchekar BS, Shah TP, Chabukswar AR. Selection of

superdisintegrant for famotidine rapidly disintegrating tablets. J Chem Pharm Res.

2010;2(2):65-72.

69. Patel HA, Patel J, Patel KN, Patel RR. Studies on formulation and in vitro evaluation

of fast dissolving tablets of domperidone. Int J Pharma Sci. 2010;2(1):470-76.

70. Jeong SH, Takaishi Y, Fu Y, Park K. Material properties for making fast dissolving

tablets by a compression method. J Mater Chem. 2008;18:3527–35.

71. Setty MC, Prasad DVK, Gupta VRM, Sa B. Development of fast dispersible

aceclofenac tablets: Effect of functionality of superdisintegrants. Indian J Pharm Sci.

2008;70(2):180-85.

72. Idson B, Lazaarus J. Semisolids. The theory and practice of industrial pharmacy, 4th

ed. Bombay: Vargehese publishing house; 1991.

73. Remington JP. The science and practice of pharmacy. New Delhi: Wolters kluwer:

2006;1.p. 770.

74. Ofner CM, Klech-Gelotte CM. Gels and jellies. In: Swarbrick J, editors.

Encyclopedia of pharmaceutical technology. 3rd ed, Vol 3, New York: Informa

healthcare; 2007.

75. Cooper G. Dispensing for pharmaceutical students. CSJ Carter, editors 12th ed.

London: Pitman publishing; 1982. p. 10.

References


76. Gohel MC, Parikh RK, Nagori SA, Shah SN, Dabhi MR. Preparation and evaluation

of soft gellan gum gel containing paracetamol. Ind J Pharm Sci. 2009;71(2):120-4.

77. Zatz JL, Kushla GP. Gels. In: Lieberman HA, Rieger MM, Banker GS, editors.

Pharmaceutical dosage forms: disperse systems. New York: Marcel Dekker; 2005. p.

399-411.

78. Dabhi M, Gohel M, Parikh R, Sheth N, Nagori S. Formulation development of

ambroxol hydrochloride soft gel with application of statistical experimental design

and response surface methodology. PDA J Pharm Sci Tech. 2011;65(1):20-31.

79. Mohapatra A, Rajesh KP, Mukesh CG. Formulation, development and evaluation of

patient friendly dosage forms of metformin, Part-II: Oral soft gel Year. Asian J

pharm. 2008;2(3):172-76.

80. Miyazaki S, Takahashi A, Itoh K, Ishitani M, Dairaku M, Togashi M, et al.

Preparation and evaluation of gel formulations for oral sustained delivery to

dysphagic patients. Drug Dev Ind Pharm. 2009;35(7):780-787.

81. Hanawa T, Wantanabe A, Tsuchiya T, Ikoma R, Hidaka M, Sugihara M. New oral

dosage form for elderly patients. II. Release behavior of benfotiamine from silk

fibroin gel. Chem Pharm Bull. 1995;43(5):872-76.

82. Florey K. Analytical profiles of drug substances. India: Rajkamal Electric Press,

Elsevier; 2005.

83. Chandak AR, Verma PR. Design and development of hydroxypropyl methycellulose

(HPMC) based polymeric films of methotrexate: physicochemical and

pharmacokinetic evaluations. Yakugaku Zasshi. 2008;128(7):1057-66.

References


84. Wang FXM, Li DH. Preparation of methotrexate gel and its quality control. Chinese J

New Drugs. 2003;12(8):631-32.

85. Wagner T, Fenneberg K. Bioavailability of cyclophosphamide from oral

formulations. Eur J Clin Pharmacol. 1984;26(2):269-70.

86. Shavi GV, Nayak UY, Reddy MS, Karthik A, Deshpande PB, Kumar AR, et al.

Sustained release optimized formulation of anastrozole-loaded chitosan microspheres:

in vitro and in vivo evaluation. J Mater Sci: Mater Med. 2011;22:865-78.

87. Agnihotri SA, Aminabhavi TM. Novel interpenetrating network chitosan-poly

(ethylene oxide-g-acrylamide) hydrogel microspheres for the controlled release of

capecitabine. Int J Pharm. 2006;324:103-15.

88. Srinivas P, Sunitha M, Babu DSR, Sadanandam M. Preparation and evaluation of

colon-specific controlled release capecitabine matrix tablets using a novel drug

carrier. Int J Pharma Sci. 2011;3(1):1152-62.

89. Leveque D, Maloisel F. Clinical pharmacokinetics of imatinib mesylate. In vivo.

2005;19:77-84.

90. Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed.

London: Pharmaceutical Press; 2009.

91. Kulkarni PK, Dixit AS, Singh BS. Evaluation of bacterial cellulose produced from

Acetobacter xylinum as pharmaceutical excipient. Amer J Drug Disc Dev. 2012;2:72-

86.

92. Shabir GA. Validation of high-performance liquid chromatography methods for

pharmaceutical analysis understanding the differences and similarities between

validation requirements of the US Food and Drug Administration, the US

References


Pharmacopeia and the International Conference on Harmonization. J Chromatogr A.

2003;987:57-66.

93. Al-Rimawi F, Kharoaf M. Analysis of chloramphenicol and its related compound 2-

amino-1-(4-nitrophenyl)propane-1,3-diol by reversed-Phase high-performance liquid

chromatography with UV detection. Chromatogr Res Int. 2011;1-6.

94. Miura M, Takahashi N, Sawada K. Quantitative determination of imatinib in human

plasma with high-performance liquid chromatography and ultraviolet detection. J

Chromatogr Sci. 2011;49:412-15.

95. USP method for HPLC analysis of methotrexate. Available from:

http://www.chem.agilent.com/Library/applications/ (PH23)5988-6394EN.pdf

(assessed Aug 2010).

96. Pani KAD, Venkata RY, Sunitha G, Rama KK, Ceema M, Rao VA. Development of

Validated Stability Indicating RP-HPLC Method for the estimation of capecitabine in

Pure and Pharmaceutical Formulations. Int J Res Pharm Biomed Res. 2011;2:175-81.

97. Abu MR. Determination of cyclophosphamide in whole blood and plasma by

reversed-phase high performance liquid chromatography. J Chromatogr Biomed Sci.

1987;422:125-34.

98. Miura M, Takahashi N, Sawada K. Quantitative determination of imatinib in human

plasma with high-performance liquid chromatography and ultraviolet detection. J

Chromatogr Sci. 2011;49:412-15.

99. Wang F, Jiang X, Wei Lu. Profiles of methotrexate in blood and CSF following

intranasal and intravenous administration to rats. Int J Pharma. 2003;63:1-7.

References


100. Mendes GD, Babadopulos T, Chen LS, Ilha JO, Magalhaes JCA, Alkharfy K, et al.

The use of healthy volunteers to evaluate bioequivalence of anti-neoplastic drugs:

pilot studies with capecitabine. J Bioequiv Availab. 2011;S1:1-8.

101. Afsharian P, Terelius Y, Hassan Z, Nilsson C, Lundgren S, Hassan M. The effect of

repeated administration of cyclophosphamide on cytochrome P450 2B in rats. Clin

Cancer Res. 2007;13(14):4218-24.

102. Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L, Gupta SK. Development

and validation of a simple liquid chromatographic method with ultraviolet detection

for the determination of imatinib in biological samples. J Chromatogr B.

2004;804:431-434.

103. Mashru RC, Sutariya VB, Sankalia MG, Parikh PP. Development and evaluation of

fast dissolving film of salbutamol sulphate. Drug Dev Ind pharm. 2005;1:25-34.

104. ElMeshad AN, ElHagrasy AS. Characterization and optimization of orodispersible

mosapride film formulations. AAPS PharmSciTech. 2011;12(4):1384-92.

105. Shah PP, Mashru RC, Rane YM, Thakkar A. Design and optimization of mefloquine

hydrochloride microparticles for bitter taste masking. AAPS PharmSciTech.

2008;9(2):377-89.

106. Prabhu P, Malli R, Koland M, Vijaynarayana K, D’Souza U, Harish NM, et al.

Formulation and evaluation of fast dissolving films of levocitirizine di hydrochloride.

Int J Pharma Investig. 2011;1(2):99-104.

107. USP35-NF30, 2012. Available from: http://www.uspnf.com/uspnf/login (accessed 2nd

Feb, 2012).

References


108. Tokuyama E, Matsunaga C, Yoshida K, Mifsud JC, Irie T, Yoshida M, et al.

Famotidine orally disintegrating tablets: Bitterness comparison of original and

generic products. Chem Pharm Bull. 2009;57(4):382-87.

109. Ousama R, Simons FER, Rawas-Qalaji M, Simons KJ. An electronic tongue:

Evaluation of the masking efficacy of sweetening and/or flavoring agents on the bitter

taste of epinephrine. AAPS PharmSciTech. 2010;11(2):550-57.

110. Shohin IE, Ramenskaya GV, Vasilenko GF, Malashenko EA. In Vitro dissolution

kinetics of amlodipine tablets marketed in russia under biowaiver conditions.

Dissolut. Technol. 2010;17(3):20-2.

111. Lalic M, Pilipovic A, Golocorbin-Kon S, Ksenija GB, Bozic K, Mikov M et al.

Comparison of dissolution profiles and serum concentrations of two lamotrigine

tablet formulations. Drugs R D. 2011;11(1):53-60.

112. Ali AH, Fakhreddin J. Pharmacokinetics of meloxicam administered as regular and

fast dissolving formulations to the rat: Influence of gastrointestinal dysfunction on the

relative bioavailability of two formulations. Eur J Pharm Biopharm. 2008;70(3):889-

94.

113. Kou W, Cai C, Xu S, Wang H, Liu J, Yang D et al. In vitro and in vivo evaluation of

novel immediate release carbamazepine tablets: Complexation with hydroxypropyl β-

cyclodextrin in the presence of HPMC. Int J Pharm. 2011;409(1-2):75–80.

114. Abed KK, Hussein AA, Ghareeb MM, Abdulrasool AA: Formulation and

optimization of orodispersible tablets of diazepam. AAPS PharmaSci Tech.

2010;11(11):356-61.

References


115. Sheshala R, Khan N, Chitneni M, Darwis Y. Formulation and In vivo evaluation of

ondansetron orally disintegrating tablets using different superdisintegrants. Arch

Pharm Res. 2011;34(11):1945-55.

116. Khalid KA, Hussein AA, Ghareeb MM, Abdulrasool AA. Formulation and

optimization of orodispersible tablets of diazepam. AAPS PharmSciTech. 2010;

11(1):356-61.

117. Arya A, Chandra A. Fast drug delivery systems: A review. Der Pharmacia Lettre.

2010;2(2):350-61.

118. Pharmacopoeia of India. Vol II. Controller of publications. Ministry of health and

family welfare; 1996.

119. Lau JH, Chang C. “TMA, DMA, DSC and TGA of lead free solders", Solder & Surf

Mt Tech. 1999;11(2):17-24.

120. Anastrozole melting point. Available from:

http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con093709.p

df (accessed on: 10th Oct, 2012).

121. Methotrexate melting point. Available from:

http://www.sciencelab.com/msds.php?msdsId=9924643 (accessed on: 10th Oct,

2012).

122. Cyclophosphamide melting point. Available from:

http://ntp.niehs.nih.gov/ntp/roc/twelfth/profiles/Cyclophosphamide.pdf (accessed on:

4th Oct, 2012).

References


123. Amala K, Rao TS, Rao AKS, Rachakonda S, Chowdary NV, Podili K. Novel

polymorphic form of imatinib mesylate and a process for its preparation. US patent

no: 0255138 A1, 2008.

124. Capecitabine melting point. Available from: http://www.lclabs.com/MSDS/C-

2799MSDS.php4 (accessed on: 2nd Oct, 2012).

125. Podczeck F, Knight PE, Newton JM. The evaluation of modified microcrystalline

cellulose for the preparation of pellets with high drug loading by extrusion/

spheronization. Int J Pharm. 2008; 350(1-2):14-54.

126. McGinity JW, Felton LA. An aqueous polymeric coating for pharmaceutical dosage

forms. 3rd ed, New York: Informa Healthcare; 2008.

127. Cilurzo F, Cupone IE, Minghetti P, Buratti S, Selmin F. Nicotine fast dissolving films

made of maltodextrin: A feasibility study, APPS Pharm Sci Tech. 2010;1(4):1511-17.

128. Snejdrova E, Dittrich M. Pharmaceutically Used Plasticizers, Recent Advances in

Plasticizers, Mohammad Luqman editors, Europe: InTech Publishers; 2012.

129. Bozdemir OA, Tutas M. Plasticizer effect on water vapour permeability properties of

locust bean gum-Based edible films. Turk J Chem. 2003; 27:773-82.

130. Suppakul P, Chalernsook B, Ratisuthawat B, Prapasitthi S, Munchukangwan K.

Plasticizer and relative humidity effects on mechanical properties of cassava flour

films. The 15th IAPRI World Conference on Packaging; 3-5 Oct, Tokyo,

Japan; 2006.

131. Aulton ME, Abdul-Razzak MH, Hogan JE. The mechanical properties of

hydroxypropylmethylcellulose films derived from aqueous systems Part 1: The

influence of Plasticizers. Drug Dev Ind Pharm. 1981;7(6):649-68.

References


132. Yellanki SK, Jagtap S, Masareddy R. Dissofilm: A novel approach for delivery of

phenobarbital: Design and characterization. J Young Pharm. 2011;3(3):181-88.

133. The function and selection of ester plasticizers. Available from:

http://www.hallstar.com/techdocs/The_Function-Selection_Ester_Plasticizers.pdf

(assessed on: 2nd Oct, 2012).

134. McGinity J, Felton LA. Aqueous polymeric coatings for pharmaceutical dosage

forms, 3rd ed. New York: Informa healthcare; 2008.

135. Saringat HB, Alfadol KI, Khan GM. The influence of different plasticizers on some

physical and mechanical properties of hydroxypropyl methylcellulose free films. Pak

J Pharm Sci. 2005;18(3):25-38.

136. Interactive effects of water-glycerol and water-sorbitol on physical properties

ofkonjac glucomannan films. Available from:

http://eprints.usm.my/10163/1/Interactive_Effects_of_Water-Glycerol_and_Water-

Sorbitol_on_Physical_Properties_of_Konjac_Glucomannan_Films_(PPTekIndustri).p

df (assessed on: 2nd Oct, 2012).

137. Limpongsa E, Umprayn K. Preparation and evaluation of diltiazem hydrochloride

diffusion-controlled transdermal delivery system. AAPS PharmSciTech. 2008; 9(2):

464-70.

138. Muzib YI, Kumari KS. Mucoadhesive buccal films of glibenclamide: Development

and evaluation. Int J Pharma Investig. 2011;1(1):42-7.

139. Mohamed MI, Mohamed H, Mohamed AM. Buccal mucoadhesive films containing

antihypertensive drug: In vitro/in vivo evaluation. J Chem Pharm Res. 2011;

3(6):665-86.

References


140. Sapkal NP, Kilor VA, Daud AS, Bonde MN. Development of fast dissolving oral thin

films of ambroxol hydrochloride: effect of formulation variables. J Adv Pharm Res.

2011;2(2):102-9.

141. Perfetti G, Laarhoven BL, Meesters GMH. Influence of polymer coating on strength

and damage of granules: mechanical properties of polymer films. Available from:

http: //www.biopowders.net/Papers/Partec%20P10.pdf (assessed on: Jan 10th, 2012).

142. Sugar substitute. Available from: http://en.wikipedia.org/wiki/Sucralose. (assessed

on: 3rd Oct, 2012).

143. Li L, Naini V, Ahmed SU. Utilization of a modified special-cubic design and an

electronic tongue for bitterness masking formulation optimization. J Pharm Sci.

2007;96(10):2723-34.

144. Bitterness masking efficiency testing. Application to pharmaceutical oral

formulations. Available from:

http://www.labsolutions.com.br/downloads/ap03_bitterness_masking.pdf (assessed

on: 3rd Oct, 2012).

145. Yadav SK, Niranjan SK, Jain SK, Singh M. Mouth dissolving tablet: Approaches

technology. Int Res J Tech. 2012;3(10):43-7.

146. Perea S, Pennick GJ, Modak A, Fothergill AW, Sutton DA, Sheehan DJ, et al.

Comparison of high-performance liquid chromatographic and microbiological

methods for determination of voriconazole levels in plasma. Antimicrob Agents

Chemother. 2000;44(5):1209-13.

147. Glycerol. Available from: http://en.wikipedia.org/wiki/Glycerol (assessed on: 3rd

Oct, 2012).

References


148. Fule RA, Meer TS, Sav AR, Amin PD. Dissolution rate enhancement and

physicochemical characterization of artemether and lumefantrine solid dispersions.

Int J Drug Deliv. 2012;4(1):95-106.

149. Liua Y, Suna C, Hao Y, Jianga T, Zhenga L, Wanga S. Mechanism of dissolution

enhancement and bioavailability of poorly water soluble celecoxib by preparing

stable amorphous nanoparticles. J Pharm Pharmaceut Sci. 2010;13(4):589-606.

150. Alanazi FK, Rahman AAA, Mahrous GM, Alsarra IA. Formulation and

physicochemical characterization of buccoadhesive films containing ketorolac. J

Drug Del Sci. 2007;17(3):183-92.

151. Neusilin US2. The extraordinary excipient for solid dosage forms. Technical

newsletter/Nov 2007. Available From:

http://www.fujichemical.co.jp/english/newsletter/newsletter_pharma_0711.html

(assessed on: 10th Apr, 2011).

152. Magnesium stearate. Available From:

http://soe.rutgers.edu/sites/default/files/gset/PharmaDC.pdf (assessed on: 5th Apr,

2012).

153. Fini A, Bergamante V, Ceschel GC, Ronchi C, Carlos AFM: Fast dispersible/slow

releasing ibuprofen tablets. Eur J Pharm and Biopharm. 2008;69(1):335–341.

154. Mannitol. Available From: http://en.wikipedia.org/wiki/Mannitol (assessed on: 10th

Apr, 2012).

155. Flavor. Available From: http://en.wikipedia.org/wiki/Flavor (assessed on: 12th Apr,

2012).

References


156. Crospovidone superdisintegrants. Available From:

http://www.ashland.com/Ashland/Static/Documents/ASI/PC_11319_Polyplasdone_O

verview.pdf (assessed on: 21th Oct, 2012).

157. Pandya VM, Patel DJ, Patel JK, Patel RP. Formulation, characterization and

optimization of fast-dissolve tablets containing celecoxib solid dispersion. Dissolut

Technol. 2009;16:22-7.

158. Durig T, Fassihi R. Mechanistic evaluation of binary effects of magnesium stearate

and talc as dissolution retardants at 85 % drug loading in an experimental extended

release formulation. J Pharm Sci. 1997;86:1092-98.

159. Mohanachandran PS, Sindhumol PG, Kiran TS. Superdisintegrants: An overview. Int

J Pharm Sci Rev and Res. 2011;6:105-9.

160. Velmurugan S, Vinushitha. Oral disintegrating tablets: An overview. Int J Chem

Pharm Sci. 2010;1(2):1-12.

161. Patil C, Das S. Effect of various superdisintegrants on the drug release profile and

disintegration time of lamotrigine orally disintegrating tablets. Afr J Pharm Pharacol.

2011;5:76-82.

162. Battu SK, Repka MA, Majumdar S, Madhusudan RY. Formulation and evaluation of

rapidly disintegrating fenoverine tablets: effect of superdisintegrants. Drug Dev Ind

Pharm. 2007;33(11):1225-32.

163. Late SG, Yu YY, Banga AK. Effects of disintegration-promoting agent, lubricants

and moisture treatment on optimized fast disintegrating tablets. Int J Pharm. 2009;

365(1-2):4-11.

References


164. U.S. Food and drug administration, Guidance for industry orally disintegrating

tablets. Available From:

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/G

uidances/ucm070578.pdf (Assessed on: 15th Feb, 2012).

165. Bi Y, Sunada H, Yorinobu Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation

of a compressed tablet rapidly disintegrating in the oral cavity. Chem Pharm

Bull. 1996;44:2121–7.

166. Watanabe Y, Koizumi K, Zama Y, Kiriyama M, Matsumoto Y, Matsumoto M. New

compressed tablet rapidly disintegrating in saliva in the mouth using crystalline

cellulose and a disintegrant. Biol Pharm Bull. 1995;18:1308-10.

167. Gupta A, Hunt RL, Shah RB, Sayeed VA, Khan MA. Disintegration of highly soluble

immediate release tablets: A surrogate for dissolution. AAPS

PharmSciTech. 2009;10(2):495-9.

168. Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric

floating and sustained release preparation. I. Application of calcium silicate as a

floating carrier. Chem Pharm Bull. 1996;44:1361–6.

169. Zhao N, Augsburger LL. The influence of swelling capacity of superdisintegrants in

different pH media on the dissolution of hydrochlorothiazide from directly

compressed tablets. AAPS PharmSciTech. 2005;6(1):120-6.

170. Bala R, Khanna S, Pawar P. Polymers in fast disintegrating tablets – A review. Asian

J Pharm Clin Res. 2012;5(2)8-14.

171. Pabari RM, Ramtoola Z. Effect of a disintegration mechanism on wetting, water

absorption, and disintegration time of orodispersible tablets. J Young Pharmacists

2012;4:157-63.

References


172. Mannitol. Available From: http://en.wikipedia.org/wiki/Mannitol (Assessed on: 20th

Oct, 2012).

173. Antimicrobial Preservatives Part Two: Choosing a Preservative. Available From:

http://www.americanpharmaceuticalreview.com/Featured-Articles/38885-

Antimicrobial-Preservatives-Part-Two-Choosing-a-Preservative/ (Assessed on: 20th

Oct, 2012).

174. Compounding gels Available From:

http://www.perrigo.com/business/pdfs/Sec%20Artem%204.5.pdf (Assessed on: 20th

Oct, 2012).

175. Gerentes P, Vachoud L, Doury J, Domard A. Study of a chitin-based gel as injectable

material in periodontal surgery. Biomaterials 2002;23(5):1295-302.

176. Germain I, Dufresne T, Ramaswamy HS. Rheological characterization of thickened

beverages used in the treatment of dysphagia. J Food Eng. 2006;73(1):64-74.

177. Steele CM, Van Lieshout PH, Goff HD. The rheology of liquids: A comparison of

clinicians’ subjective impressions and objective measurement. Dysphagia

2003;18:182-95.

178. El-Kamel A, Al-Dosari H, Al-Jenoobi F. Environmentally responsive ophthalmic gel

formulation of carteolol hydrochloride. Drug Deliv. 2006;13(1):55-59.

179. Viral F, Patel NM. Statistical evaluation of influence of viscosity and content polymer

on dipyridamole release from floating matrix tablets: A technical note. AAPS

PharmSciTech. 2007;8(3):E1-E5.

180. Garg R, Gupta G. Preparation and evaluation of gastroretentive floating tablets of

silymarin. Chem Pharm Bull. 2009;57(6):545-549.